Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusen Pharmaceutical Co., Ltd. has announced the passing of its Chairman, Mr. Cao Changcheng, and the appointment of his son, Mr. Cao Zhiming, as the new Chairman. The company has assured investors that this transition will not affect its business operations. Mr. Zhiming, with over 12 years of experience in securities and corporate finance, holds a significant stake in the company and is set to continue the strategic direction established by the Board.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.